Tirofiban usage and prognosis after myocardial infarction

Kaynakça (2)

1. Kaymaz C, Keleş N, Özdemir N, Tanboğa İH, Demircan HC, Can MM, et al. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI. Anatol J Cardiol 2014 Dec 25. Epub ahead of print
2. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. Task Force on the management of ST-segment elevation acute myocar-dial infarction of the European Society of Cardiology. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619. [CrossRef] 3. Chan AW, Bakar SN, Brown RI, Kuritzky R, Lalani A, Gordon W, et al. In-hospital outcomes of a regional ST-segment elevation myocardial infarction acute transfer and repatriation program. Can J Cardiol 2011; 27: 664.e1-8. [CrossRef] 4. Dagres N, Hindricks G. Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J 2013; 34: 1964-71. [CrossRef] 5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21. [CrossRef]